Stage IIIB Uveal Melanoma AJCC v7

Stage IIIB includes: (T3d, N0, M0); (T4b-c, N0, M0).  T3d: Ciliary body and choroid: Tumor size category 3 with ciliary body involvement and extraocular extension less than or equal to 5 mm in diameter.  T4b: Iris: Tumor with extrascleral extension more than 5 mm in diameter.  Ciliary body and choroid: Tumor size category 4 with ciliary body involvement.  T4c: Ciliary body and choroid: Tumor size category 4 without ciliary body involvement but with extraocular extension less than or equal to 5 mm in diameter.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 7th ed.)


Stage IIIC Uveal Melanoma AJCC v7

biolink:Disease biolink:DiseaseOrPhenotypicFeature biolink:BiologicalEntity biolink:ThingWithTaxon biolink:NamedThing

Stage IIIC includes: T4d-e, N0, M0.  T4d: Ciliary body and choroid: Tumor size category 4 with ciliary body involvement and extraocular extension less than or equal to 5 mm in diameter.  T4e: Ciliary body and choroid: Any tumor size category with extraocular extension more than 5 mm in diameter.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 7th ed.)


Leiomyosarcoma recurrent

The reemergence of leiomyosarcoma after a period of remission


Mycosis fungoides/Sezary syndrome stage I

Stage I includes: IA (T1, N0, M0, B0-1); IB (T2, N0, M0, B0-1). T1: Limited patches, papules, and/or plaques covering less than 10% of the skin surface.  May further stratify into T1a (patch only) vs. T1b (plaque +/- patch).  T2: Patches, papules, or plaques covering 10% or more of the skin surface.  May further stratify into T2a (patch only) vs. T2b (plaque +/- patch).  N0: No clinically abnormal peripheral lymph nodes; biopsy not required.  M0: No visceral organ involvement.  B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells).  B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2.  (AJCC 7th ed.)


Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7

Stage IB includes: T2, N0, M0, B0-1. T2: Patches, papules, or plaques covering 10% or more of the skin surface.  May further stratify into T2a (patch only) vs. T2b (plaque +/- patch).  N0: No clinically abnormal peripheral lymph nodes; biopsy not required.  M0: No visceral organ involvement.  B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells).  B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2.  (AJCC 7th ed.)


Mycosis fungoides/Sezary syndrome stage II

Stage II includes: IIA (T1-2, N1-2, M0, B0-1); IIB (T3, N0-2, M0, B0-1). T1: Limited patches, papules, and/or plaques covering less than 10% of the skin surface.  May further stratify into T1a (patch only) vs. T1b (plaque +/- patch).  T2: Patches, papules, or plaques covering 10% or more of the skin surface.  May further stratify into T2a (patch only) vs. T2b (plaque +/- patch).  T3: One or more tumors (equal or greater than 1 cm diameter).  N0: No clinically abnormal peripheral lymph nodes; biopsy not required.  N1: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or NCI LN0-2.  N2: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3.  M0: No visceral organ involvement.  B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells).  B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2.  (AJCC 7th ed.)


Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7

Stage IIA includes: T1-2, N1-2, M0, B0-1.  T1: Limited patches, papules, and/or plaques covering less than 10% of the skin surface.  May further stratify into T1a (patch only) vs. T1b (plaque +/- patch).  T2: Patches, papules, or plaques covering 10% or more of the skin surface.  May further stratify into T2a (patch only) vs. T2b (plaque +/- patch).  N1: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or NCI LN0-2.  N2: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3.  M0: No visceral organ involvement.  B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells).  B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2.  (AJCC 7th ed.)


Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7

Stage IIB includes: T3, N0-2, M0, B0-1.  T3: One or more tumors (equal or greater than 1 cm diameter).  N0: No clinically abnormal peripheral lymph nodes; biopsy not required.  N1: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or NCI LN0-2.  N2: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3.  M0: No visceral organ involvement.  B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells).  B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2.  (AJCC 7th ed.)


Leukemic infiltration of skin

Cutaneous involvement by an acute or chronic leukemia.


Stage III Mycosis Fungoides and Sezary Syndrome AJCC v7

Stage III includes: (T4, N0-2, M0, B0-1); IIIA (T4, N0-2, M0, B0); IIIB (T4, N0-2, M0, B1). T4: Confluence of erythema covering 80% or more of body surface area.  N0: No clinically abnormal peripheral lymph nodes; biopsy not required.  N1: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or NCI LN0-2.  N2: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3.  M0: No visceral organ involvement.  B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells).  B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2.  (AJCC 7th ed.)


Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v7

Stage IIIA includes: T4, N0-2, M0, B0.  T4: Confluence of erythema covering 80% or more of body surface area.  N0: No clinically abnormal peripheral lymph nodes; biopsy not required.  N1: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or NCI LN0-2.  N2: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3.  M0: No visceral organ involvement.  B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells).  (AJCC 7th ed.)


Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v7

Stage IIIB includes: T4, N0-2, M0, B1. T4: Confluence of erythema covering 80% or more of body surface area.  N0: No clinically abnormal peripheral lymph nodes; biopsy not required.  N1: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or NCI LN0-2.  N2: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3.  M0: No visceral organ involvement.  B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2.  (AJCC 7th ed.)


Liposarcoma metastatic

A liposarcoma that has metastasized to a secondary site.


Mycosis fungoides/Sezary syndrome stage IV

Stage IV includes: IVA1 (T1-4, N0-2, M0, B2); IVA2 (T1-4, N3, M0, B0-2); IVB (T1-4, N0-3, M1, B0-2). T1: Limited patches, papules, and/or plaques covering less than 10% of the skin surface.  May further stratify into T1a (patch only) vs. T1b (plaque +/- patch).  T2: Patches, papules, or plaques covering 10% or more of the skin surface.  May further stratify into T2a (patch only) vs. T2b (plaque +/- patch).  T3: One or more tumors (equal or greater than 1 cm diameter).  T4: Confluence of erythema covering 80% or more of body surface area.  N0: No clinically abnormal peripheral lymph nodes; biopsy not required.  N1: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or NCI LN0-2.  N2: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3.  N3: Clinically abnormal peripheral lymph nodes; histopathology Dutch grades 3-4 or NCI LN4; clone positive or negative.  M0: No visceral organ involvement.  M1: Visceral involvement (must have pathology confirmation and organ involved should be specified).  B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells).  B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2.  B2: High blood tumor burden: 1000/microL Sezary cells or more with positive clone.  (AJCC 7th ed.)


Stage IVA Mycosis Fungoides and Sezary Syndrome AJCC v7

Stage IVA includes: IVA1 (T1-4, N0-2, M0, B2); IVA2 (T1-4, N3, M0, B0-2). T1: Limited patches, papules, and/or plaques covering less than 10% of the skin surface.  May further stratify into T1a (patch only) vs. T1b (plaque +/- patch).  T2: Patches, papules, or plaques covering 10% or more of the skin surface.  May further stratify into T2a (patch only) vs. T2b (plaque +/- patch).  T3: One or more tumors (equal or greater than 1 cm diameter).  T4: Confluence of erythema covering 80% or more of body surface area.  N0: No clinically abnormal peripheral lymph nodes; biopsy not required.  N1: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or NCI LN0-2.  N2: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3.  N3: Clinically abnormal peripheral lymph nodes; histopathology Dutch grades 3-4 or NCI LN4; clone positive or negative.  M0: No visceral organ involvement.  B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells).  B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2.  B2: High blood tumor burden: 1000/microL Sezary cells or more with positive clone.  (AJCC 7th ed.)


Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v7

Stage IVB includes: T1-4, N0-3, M1, B0-2. T1: Limited patches, papules, and/or plaques covering less than 10% of the skin surface.  May further stratify into T1a (patch only) vs. T1b (plaque +/- patch).  T2: Patches, papules, or plaques covering 10% or more of the skin surface.  May further stratify into T2a (patch only) vs. T2b (plaque +/- patch).  T3: One or more tumors (equal or greater than 1 cm diameter).  T4: Confluence of erythema covering 80% or more of body surface area.  N0: No clinically abnormal peripheral lymph nodes; biopsy not required.  N1: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or NCI LN0-2.  N2: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3.  N3: Clinically abnormal peripheral lymph nodes; histopathology Dutch grades 3-4 or NCI LN4; clone positive or negative.  M1: Visceral involvement (must have pathology confirmation and organ involved should be specified).  B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells).  B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2.  B2: High blood tumor burden: 1000/microL Sezary cells or more with positive clone.  (AJCC 7th ed.)


Liposarcoma recurrent

The reemergence of liposarcoma after a period of remission.


Metastatic Malignant Peripheral Nerve Sheath Tumor

The presence of malignant Schwann cell growth (benign variant is known as neurofibroma) at a site removed from the primary site of tumor growth.


Recurrent Malignant Peripheral Nerve Sheath Tumor

The reemergence of malignant peripheral nerve sheath tumor after a period of remission.


Synovial sarcoma metastatic

A synovial sarcoma that has metastasized to other anatomic sites.


Synovial sarcoma recurrent

The reemergence of synovial sarcoma after a period of remission


Hodgkin's disease mixed cellularity recurrent

The reemergence of mixed cellularity classic Hodgkin lymphoma after a period of remission.


Hodgkin's disease mixed cellularity refractory

Mixed cellularity classic Hodgkin lymphoma that is resistant to treatment.


Hodgkin's disease mixed cellularity stage I site unspecified

Ann Arbor Classification: Stage I: Involvement of a single lymph node region (I); or localized involvement of a single extralymphatic organ or site in the absence of any lymph node involvement (IE) (rare in Hodgkin lymphoma).


Hodgkin's disease mixed cellularity stage IV

Ann Arbor Classification: Stage IV: Diffuse or disseminated involvement of one or more extralymphatic organs, with or without associated lymph node involvement; or isolated extralymphatic organ involvement in the absence of adjacent regional lymph node involvement, but in conjunction with disease in distant site(s); or any involvement of the liver or bone marrow, lungs (other than by direct extension from another site), or cerebrospinal fluid.


Hodgkin's disease nodular sclerosis recurrent

The reemergence of nodular sclerosis classic Hodgkin lymphoma after a period of remission.


malignant neoplasm of breast stage I

Stage I includes: IA: T1, N0, M0 and IB: (T0, N1mi, M0); (T1, N1mi, M0).  T1: Tumor 20 mm or less in greatest dimension.  T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension.  T0: No evidence of primary tumor.  N0: No regional lymph node metastasis.  N1mi: Nodal micrometastases.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 7th Ed.)


Stage III Breast Cancer AJCC v7

Stage III includes: IIIA : (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N1, M0); (T3, N2, M0), IIIB: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0), and IIIC: (any T, N3, M0).  T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or skin nodules).  N2: Metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted; or in clinically detected ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastases.  N3: Metastases in ipsilateral infraclavicular (level III) axillary lymph nodes(s) with or without level I, II axillary lymph node involvement; or in clinically detected ipsilateral internal mammary lymph node(s) with clinically evident level I, II axillary lymph node metastases; or metastases in ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node involvement.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 7th Ed.)


Stage IIIC Breast Cancer AJCC v7

Stage IIIC includes: Any T, N3, M0.  N3: Metastases in ipsilateral infraclavicular (level III) axillary lymph nodes(s) with or without level I, II axillary lymph node involvement; or in clinically detected ipsilateral internal mammary lymph node(s) with clinically evident level I, II axillary lymph node metastases; or metastases in ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node involvement.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 7th Ed.)


Hodgkin's disease nodular sclerosis refractory

Nodular sclerosis classic Hodgkin lymphoma that is resistant to treatment.


Hodgkin's disease nodular sclerosis stage I


Hodgkin's disease nodular sclerosis stage IV


B-cell lymphoma recurrent

The reemergence of B-cell non-Hodgkin lymphoma after a period of remission.


Stage III Cutaneous Melanoma AJCC v7

Stage III includes: Any T, N1-3, M0.  Stage III is divided into three pathologic subgroups: IIIA, IIIB, and IIIC.  There are no clinical subgroups for stage III.  N1: Cutaneous melanoma with metastasis in one regional lymph node.  N2: Cutaneous melanoma with metastases in 2-3 regional lymph nodes or in transit met(s)/satellite(s) without metastatic nodes.  N3: Cutaneous melanoma with 4 or more metastatic nodes, or matted nodes, or in transit met(s)/satellite(s) with metastatic node(s).  M0: No detectable evidence of distant metastases. (from AJCC 7th Ed.)


B-cell lymphoma refractory

B-cell non-Hodgkin lymphoma that is resistant to treatment.


B-cell lymphoma stage II

Ann Arbor Classification: Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm (II); or localized involvement of a single extralymphatic organ or site in association with regional lymph node involvement with or without involvement of other lymph node regions on the same side of the diaphragm (IIE). The number of regions involved may be indicated by a subscript (e.g., II3).


B-cell lymphoma stage III

Ann Arbor Classification: Stage III: Involvement of lymph node regions on both sides of the diaphragm (III), which also may be accompanied by extralymphatic extension in association with adjacent lymph node involvement (IIIE) or by involvement of the spleen (IIIS) or both (IIIE,S).


B-cell small lymphocytic lymphoma refractory

B-cell small lymphocytic lymphoma that is resistant to treatment.


Burkitt's lymphoma refractory

Burkitt lymphoma that is resistant to treatment.


Diffuse large B-cell lymphoma recurrent

The reemergence of diffuse large B-cell lymphoma after a period of remission.


Diffuse large B-cell lymphoma refractory

Diffuse large B-cell lymphoma that is resistant to treatment.


Stage I Diffuse Large B-Cell Lymphoma

Ann Arbor Classification: Stage I: Involvement of a single lymph node region (I); or localized involvement of a single extralymphatic organ or site in the absence of any lymph node involvement (IE).


Stage II Diffuse Large B-Cell Lymphoma

Ann Arbor Classification: Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm (II); or localized involvement of a single extralymphatic organ or site in association with regional lymph node involvement with or without involvement of other lymph node regions on the same side of the diaphragm (IIE).


Stage IV Diffuse Large B-Cell Lymphoma

Ann Arbor Classification: Stage IV: Diffuse or disseminated involvement of one or more extralymphatic organs, with or without associated lymph node involvement; or isolated extralymphatic organ involvement in the absence of adjacent regional lymph node involvement, but in conjunction with disease in distant site(s); or any involvement of the liver or bone marrow, lungs (other than by direct extension from another site), or cerebrospinal fluid.


Follicular lymphoma refractory

Follicular lymphoma grade I, II, III that is resistant to treatment.


Mantle cell lymphoma refractory

Mantle cell lymphoma resistant to treatment.


Nodal marginal zone B-cell lymphoma stage II


Nodal marginal zone B-cell lymphoma stage III


Nodal marginal zone B-cell lymphoma stage IV


Precursor B-lymphoblastic lymphoma recurrent

The reemergence of B-lymphoblastic lymphoma after a period of remission.


Precursor B-lymphoblastic lymphoma refractory

B-lymphoblastic lymphoma that does not respond to treatment.


Precursor B-lymphoblastic lymphoma stage I


Primary mediastinal large B-cell lymphoma recurrent

The reemergence of primary mediastinal large B-cell lymphoma after a period of remission.


Primary mediastinal large B-cell lymphoma refractory

Primary mediastinal large B-cell lymphoma that is resistant to treatment.


Primary mediastinal large B-cell lymphoma stage I


Primary mediastinal large B-cell lymphoma stage II


Primary mediastinal large B-cell lymphoma stage III


Primary mediastinal large B-cell lymphoma stage IV


Stage IV Extragonadal Non-Seminomatous Germ Cell Tumor


Stage III Lung Cancer AJCC v7

Stage III includes: IIIA (T1a, N2, M0); (T1b, N2, M0); (T2a, N2, M0); (T2b, N2, M0); (T3, N1, M0); (T3, N2, M0); (T4, N0, M0); (T4, N1, M0) and IIIB (T1a, N3, M0); (T1b, N3, M0); (T2a, N3, M0); (T2b, N3, M0); (T3, N3, M0); (T4, N2, M0); (T4, N3, M0).  T4: Lung cancer with a tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, and separate tumor nodule(s) in a different ipsilateral lobe.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension.  N2: Lung cancer with metastasis to ipsilateral mediastinal and/or subcarinal lymph nodes.  N3: Lung cancer with metastasis to contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph nodes.  M0: No distant metastasis. (AJCC 7th ed.)


Stage IV Lung Cancer AJCC v7

Stage IV includes: (Any T, Any N, M1a); (Any T, Any N, M1b).  M1a: Lung cancer with separate tumor nodule(s) in a contralateral lobe; tumor with pleural nodules or malignant pleural (or pericardial) effusion.  M1b: Distant metastasis. (AJCC 7th ed.)


Stage II Nasopharyngeal Carcinoma AJCC v7

Stage II includes: (T1, N1, M0); (T2, N0, M0); (T2, N1, M0).  T1: Nasopharyngeal cancer with tumor confined to the nasopharynx, or tumor extending to oropharynx and/or nasal cavity without parapharyngeal extension.  Parapharyngeal extension denotes posterolateral infiltration of tumor. T2: Nasopharyngeal cancer with parapharyngeal extension.  Parapharyngeal extension denotes posterolateral infiltration of tumor.  N0: No regional lymph node metastasis. N1: Nasopharyngeal cancer with unilateral metastasis in cervical lymph node(s), 6 cm or less in greatest dimension, above the supraclavicular fossa, and/or unilateral or bilateral, retropharyngeal lymph nodes, 6 cm or less in greatest dimension.  Midline nodes are considered ipsilateral nodes.  M0: No distant metastasis. (AJCC 7th ed.)


Stage III Nasopharyngeal Carcinoma AJCC v7

Stage III includes: (T1, N2, M0); (T2, N2, M0); (T3, N0, M0); (T3, N1, M0); (T3, N2, M0). T1: Nasopharyngeal cancer with tumor confined to the nasopharynx, or tumor extending to oropharynx and/or nasal cavity without parapharyngeal extension.  Parapharyngeal extension denotes posterolateral infiltration of tumor. T2: Nasopharyngeal cancer with parapharyngeal extension.  Parapharyngeal extension denotes posterolateral infiltration of tumor.  T3: Nasopharyngeal cancer with tumor involving bony structures of skull base and/or paranasal sinuses.  N0: No regional lymph node metastasis. N1: Nasopharyngeal cancer with unilateral metastasis in cervical lymph node(s), 6 cm or less in greatest dimension, above the supraclavicular fossa, and/or unilateral or bilateral, retropharyngeal lymph nodes, 6 cm or less in greatest dimension.  Midline nodes are considered ipsilateral nodes.  N2: Nasopharyngeal cancer with bilateral metastasis in cervical lymph node(s), 6 cm or less in greatest dimension, above the supraclavicular fossa.  Midline nodes are considered ipsilateral nodes. M0: No distant metastasis. (AJCC 7th ed.)


Stage IV Nasopharyngeal Carcinoma AJCC v7

Stage IV includes: IVA: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0); IVB (Any T, N3, M0); IVC (Any T, Any N, M1). T4: Nasopharyngeal cancer with intracranial extension and/or involvement of cranial nerves, hypopharynx, orbit, or with extension to the infratemporal fossa/masticator space.  N0: No regional lymph node metastasis. N1: Nasopharyngeal cancer with unilateral metastasis in cervical lymph node(s), 6 cm or less in greatest dimension, above the supraclavicular fossa, and/or unilateral or bilateral, retropharyngeal lymph nodes, 6 cm or less in greatest dimension.  Midline nodes are considered ipsilateral nodes.  N2: Nasopharyngeal cancer with bilateral metastasis in cervical lymph node(s), 6 cm or less in greatest dimension, above the supraclavicular fossa.  Midline nodes are considered ipsilateral nodes. N3: Nasopharyngeal cancer with metastasis in a lymph node (s) more than 6 cm in greatest dimension and/or to supraclavicular fossa.  Supraclavicular zone or fossa is relevant to the staging of nasopharyngeal carcinoma and is the triangular region originally described by Ho.  It is defined by three points: (1) the superior margin of the sternal end of the clavicle, (2) the superior margin of the lateral end of the clavicle, (3) the point where the neck meets the shoulder.  This would include caudal portions of levels IV and VB.  All cases with lymph nodes (whole or part) in the fossa are considered N3b.  M0: No distant metastasis. M1: Distant metastasis. (AJCC 7th ed.)


Testicular choriocarcinoma stage III

Stage III includes: Any pT/TX, Any N, M1, SX.  M1: Distant metastasis. SX: Marker studies not available or not performed.  (AJCC 6th and 7th eds.)


Testicular choriocarcinoma stage I

Stage I includes: pT1-4, N0, M0, SX.  pT1: Tumor limited to the testis and epididymis without vascular/lymphatic invasion; tumor may invade into the tunica albuginea but not the tunica vaginalis.  pT2: Tumor limited to the testis and epididymis with vascular/lymphatic invasion, or tumor extending through the tunica albuginea with involvement of the tunica vaginalis.  pT3: Tumor invades the spermatic cord with or without vascular/lymphatic invasion.  pT4: Tumor invades the scrotum with or without vascular/lymphatic invasion.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  SX: Marker studies not available or not performed. (AJCC 6th and 7th eds.)


Testicular embryonal carcinoma stage II

Stage II includes: Any pT/TX, N1-3, M0, SX.  pTX: Primary tumor cannot be assessed.  N1: Metastasis with a lymph node mass 2 cm or less in greatest dimension; or multiple lymph nodes, none more than 2cm in greatest dimension.  N2: Metastasis with a lymph node mass more than 2 cm but not more than 5 cm in greatest dimension; or multiple lymph nodes, any one mass greater than 2 cm but not more than 5 cm in greatest dimension.  N3: Metastasis with a lymph node mass more than 5 cm in greatest dimension. M0: No distant metastasis. SX: Marker studies not available or not performed.  (AJCC 6th and 7th eds.)


Testicular embryonal carcinoma stage III


Stage IV Penile Cancer AJCC v7

Stage IV includes: (T4, Any N, M0); (Any T, N3, M0); (Any T, Any N, M1).  T4: Tumor invades other adjacent structures.  cN3: Palpable fixed inguinal nodal mass or pelvic lymphadenopathy unilateral or bilateral.  pN3: Extranodal extension of lymph node metastasis or pelvic lymph node(s) unilateral or bilateral.  M0: No distant metastasis. M1: Distant metastasis (lymph node metastasis outside of the true pelvis in addition to visceral or bone sites).  (AJCC 7th ed.)


Stage III Prostate Cancer AJCC v7

Stage III includes: T3a-b, N0, M0, Any PSA, Any Gleason.  cT3a: Tumor with extracapsular extension (unilateral or bilateral).  pT3a: Tumor with extraprostatic extension or microscopic invasion of bladder neck.  T3b: Tumor invades seminal vesicle(s).  cN0: No regional lymph node metastasis.  pN0: No positive regional nodes.  M0: No distant metastasis.  (AJCC 7th ed.)


Stage IV Prostate Cancer AJCC v7

Stage IV includes: (T4, N0, M0, Any PSA, Any Gleason); (Any T, N1, M0, Any PSA, Any Gleason); (Any T, Any N, M1, Any PSA, Any Gleason). cT4: Tumor is fixed or invades adjacent structures other than seminal vesicles such as external sphincter, rectum, bladder, levator muscles, and/or pelvic wall.  pT4: Invasion of rectum, levator muscles, and/or pelvic wall.  N1: Metastasis in regional lymph node(s).  M1: Distant metastasis.  (AJCC 7th ed.)


Stage II Renal Cell Cancer AJCC v7

Stage II includes: T2, N0, M0.  T2: Lesions have been divided into T2a and T2b.  T2a is defined as tumor more than 7 cm but less than or equal to 10 cm in greatest dimension, limited to the kidney.  T2b is defined as tumor greater than 10 cm, limited to the kidney.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 7th ed.)


Stage III Renal Cell Cancer AJCC v7

Stage III includes: (T1 or T2, N1, M0); (T3, N0 or N1, M0).  T1: Lesions have been divided into T1a and T1b.  T1a is defined as tumor 4 cm or less in greatest dimension, limited to the kidney.  T1b is defined as tumor greater than 4 cm but not more than 7 cm in greatest dimension, limited to the kidney. T2: Lesions have been divided into T2a and T2b.  T2a is defined as tumor more than 7 cm but less than or equal to 10 cm in greatest dimension, limited to the kidney.  T2b is defined as tumor greater than 10 cm, limited to the kidney.  T3: Tumor extends into major veins or perinephric tissues, but not into the ipsilateral adrenal gland and not beyond Gerota's fascia. Lesions have been divided into T3a, T3b, and T3c. T3a: Tumor grossly extends into the renal vein or its segmental (muscle containing) branches, or tumor invades perirenal and/or renal sinus fat but not beyond Gerota's fascia.  T3b: Tumor grossly extends into the vena cava below the diaphragm. T3c: Tumor grossly extends into the vena cava above the diaphragm or invades the wall of the vena cava.  N0: No regional lymph node metastasis.  N1: Metastasis in regional lymph node(s). M0: No distant metastasis. (AJCC 7th ed.)


Stage IV Renal Cell Cancer AJCC v7

Stage IV includes: (T4, Any N, M0); (Any T, Any N, M1). T4: Tumor invades beyond Gerota's fascia (including contiguous extension into the ipsilateral adrenal gland).  M0: No distant metastasis. M1: Distant metastasis. (AJCC 7th ed.)


Pediatric Disorder

A non-neoplastic or neoplastic disorder which occurs during infancy, childhood, or adolescence.


Pancreatic adenocarcinoma metastatic

An adenocarcinoma that arises from the exocrine pancreatic tissue and has metastasized to other anatomic sites.


Small intestine adenocarcinoma metastatic

An adenocarcinoma that arises from the small intestine and has metastasized to other anatomic sites.


Precursor B-lymphoblastic lymphoma stage II

Ann Arbor Classification: Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm (II); or localized involvement of a single extralymphatic organ or site in association with regional lymph node involvement with or without involvement of other lymph node regions on the same side of the diaphragm (IIE).


Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma

A T-cell non-Hodgkin lymphoma that arises from the skin and does not respond to treatment.


Bladder transitional cell carcinoma stage II

Stage II includes: (T2a, N0, M0); (T2b, N0, M0).  T2a: Tumor invades superficial muscle (inner half).  T2b: Tumor invades deep muscle (outer half).  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 6th and 7th Eds.)


Bladder transitional cell carcinoma stage III

Stage III includes: (T3a, N0, M0); (T3b, N0, M0); (T4a, N0, M0).  T3a: Tumor microscopically invades perivesical tissue.  T3b: Tumor macroscopically invades perivesical tissue (extravesical mass).  T4a: Tumor invades prostatic stroma, uterus, vagina.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 6th and 7th eds.)


Bladder transitional cell carcinoma stage IV

Stage IV includes: (T4b, N0, M0); (Any T, N1-3, M0); (Any T, Any N, M1).  T4b: Tumor invades pelvic wall, abdominal wall.  N0: No regional lymph node metastasis.  N1: Single regional lymph node metastasis in the true pelvis (hypogastric, obturator, external iliac, or presacral lymph node).  N2: Multiple regional lymph node metastases in the true pelvis (hypogastric, obturator, external iliac, or presacral lymph node metastasis).  N3: Metastasis to the common iliac lymph nodes.  M0: No distant metastasis.  M1: Distant metastasis.  (AJCC 7th ed.)


Metastatic endometrioid carcinoma

An endometrioid adenocarcinoma that has spread from its original site of growth to another anatomic site.


Vaginal adenocarcinoma metastatic

An adenocarcinoma that arises from the vagina and has metastasized to other anatomic sites.


Adenocarcinoma of the prostate metastatic

An adenocarcinoma that arises from the prostate gland and has spread to other anatomic sites.


Stage III Vulvar Cancer AJCC v7

Stage III includes: IIIA: (T1/T2, N1a/N1b, M0); IIIB: (T1/T2, N2a/N2b, M0); IIIC: (T1/T2, N2c, M0).  T1: Invasive vulvar cancer confined to the vulva or perineum.  T2: Vulvar cancer with tumor of any size with extension to adjacent perineal structures (lower/distal 1/3 urethra, lower/distal 1/3 vagina, anal involvement).  N1a: Vulvar cancer with one or two lymph node metastasis each measuring 5 mm or less.  N1b: Vulvar cancer with one lymph node metastasis measuring 5 mm or greater.  N2a: Vulvar cancer with three or more lymph node metastases each measuring 5 mm or less.  N2b: Vulvar cancer with two or more lymph node metastases measuring 5 mm or greater.  N2c: Vulvar cancer with lymph node metastasis with extracapsular spread.  M0: No distant metastasis.  (AJCC 7th ed.)


Stage IVA Vulvar Cancer AJCC v7

Stage IVA includes: (T1/T2, N3, M0); (T3, Any N, M0).  T1: Invasive vulvar cancer confined to the vulva or perineum.  T2: Vulvar cancer with tumor of any size with extension to adjacent perineal structures (lower/distal 1/3 urethra, lower/distal 1/3 vagina, anal involvement).  T3: Vulvar cancer with tumor of any size with extension to any of the following: upper/proximal 2/3 urethra, upper/proximal 2/3 vagina, bladder mucosa, rectal mucosa, or fixed to pelvic bone.  N3: Vulvar cancer with fixed or ulcerated regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 7th ed.)


Adenocarcinoma of the prostate stage I

Stage I includes: (T1a-c, N0, M0, PSA less than 10, Gleason equal or less than 6); (T2a, N0, M0, PSA less than 10, Gleason equal or less than 6); (T1-2a, N0, M0, PSA X, Gleason X).  T1a: Tumor incidental histologic finding in 5% or less of tissue resected.  T1b: Tumor incidental histologic finding in more than 5% of tissue resected.  T1c: Tumor identified by needle biopsy (e.g., because of elevated PSA).  T2a: Tumor involves one-half of one lobe or less. cN0: No regional lymph node metastasis.  pN0: No positive regional nodes.  M0: No distant metastasis.  Gleason Equal or Less than 6: Well differentiated (slight anaplasia).  Gleason X: Gleason score cannot be processed.  (AJCC 7th ed.)


Adenocarcinoma of the prostate stage II

Stage II includes: IIA (T1a-c, N0, M0, PSA less than 20, Gleason 7); (T1a-c, N0, M0, PSA equal or more than 10 and less than 20, Gleason equal or less than 6); (T2a, N0, M0, PSA less than 20, Gleason equal or less than 7); (T2b, N0, M0, PSA less than 20, Gleason equal or less than 7); (T2b, N0, M0, PSA X, Gleason X); IIB (T2c, N0, M0, Any PSA, Any Gleason); (T1-2, N0, M0, PSA equal or more than 20, Any Gleason); (T1-2, N0, M0, Any PSA, Gleason equal or more than 8).  T1a: Tumor incidental histologic finding in 5% or less of tissue resected.  T1b: Tumor incidental histologic finding in more than 5% of tissue resected.  T1c: Tumor identified by needle biopsy (e.g., because of elevated PSA).  T2a: Tumor involves one-half of one lobe or less.  T2b: Tumor involves more than one-half of one lobe, but not both lobes.  T2c: Tumor involves both lobes.  cN0: No regional lymph node metastasis.  pN0: No positive regional nodes.  M0: No distant metastasis.  Gleason 7: Moderately differentiated (moderate anaplasia).  Gleason Equal or Less than 6: Well differentiated (slight anaplasia).  Gleason equal or more than 8: Poorly differentiated/undifferentiated (marked anaplasia).  (AJCC 7th ed.)


Adenocarcinoma of the prostate stage III

Stage III includes: T3a-b, N0, M0, Any PSA, Any Gleason.  cT3a: Tumor with extracapsular extension (unilateral or bilateral).  pT3a: Tumor with extraprostatic extension or microscopic invasion of bladder neck.  T3b: Tumor invades seminal vesicle(s).  cN0: No regional lymph node metastasis.  pN0: No positive regional nodes.  M0: No distant metastasis.  (AJCC 7th ed.)


Adenocarcinoma of the prostate stage IV

Stage IV includes: (T4, N0, M0, Any PSA, Any Gleason); (Any T, N1, M0, Any PSA, Any Gleason); (Any T, Any N, M1, Any PSA, Any Gleason). cT4: Tumor is fixed or invades adjacent structures other than seminal vesicles such as external sphincter, rectum, bladder, levator muscles, and/or pelvic wall.  pT4: Invasion of rectum, levator muscles, and/or pelvic wall.  N1: Metastasis in regional lymph node(s).  M1: Distant metastasis.  (AJCC 7th ed.)


Recurrent Unspecified Lung Carcinoma

Lung carcinoma that has re-emerged after a period of remission.


Cervix Intraepithelial Neoplasia Grade 3 AJCC v7

Stage 0 includes: (Tis, N0, M0). Tis: Carcinoma in situ. N0: No regional lymph node metastasis.  M0: No distant metastasis. FIGO no longer includes stage 0. (AJCC 7th ed.)


Stage II Cervical Cancer AJCC v7

Stage II includes: II (T2, N0, M0); IIA (T2a, N0, M0); IIA1 (T2a1, N0, M0); IIA2 (T2a2, N0, M0); IIB (T2b, N0, M0); T2: Cervical carcinoma invades beyond uterus but not to pelvic wall or to lower third of vagina. T2a: Tumor without parametrial invasion.  T2a1: Clinically visible lesion 4.0 cm or less in greatest dimension.  T2a2: Clinically visible lesion more than 4.0 cm in greatest dimension.  T2b: Tumor with parametrial invasion.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


Stage IIA Cervical Cancer AJCC v7

Stage IIA includes: IIA (T2a, N0, M0); IIA1 (T2a1, N0, M0); IIA2 (T2a2, N0, M0).  T2a: Tumor without parametrial invasion.  T2a1: Clinically visible lesion 4.0 cm or less in greatest dimension.  T2a2: Clinically visible lesion more than 4.0 cm in greatest dimension.  N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 7th ed.)


Stage IV Fallopian Tube Cancer AJCC v6 and v7

Stage IV includes: (Any T, Any N, M1).  M1: Distant metastasis (excludes metastasis within the peritoneal cavity). (AJCC 6th and 7th eds.)


Stage 0 Uterine Corpus Cancer

Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ. N0: No regional lymph node metastasis. M0: No distant metastasis.  This staging applies to carcinomas and carcinosarcomas.  FIGO no longer includes Stage 0 (Tis). (AJCC 7th ed.)


Stage I Uterine Corpus Cancer

Stage I includes: I (T1, N0, M0); IA: (T1a, N0, M0); IB (T1b, N0, M0). T1: Tumor confined to corpus uteri. T1a: Tumor limited to the endometrium or invades less than one-half of the myometrium. T1b: Tumor invades one-half or more of the myometrium. N0: No regional lymph node metastasis. M0: No distant metastasis. This staging applies to carcinomas and carcinosarcomas. (AJCC 7th ed.)


Stage II Uterine Corpus Cancer

Stage II includes: T2, N0, M0.  T2: Tumor invades stromal connective tissue of the cervix but does not extend beyond uterus.  Endocervical glandular involvement only should be considered as Stage I and not as Stage II.  N0: No regional lymph node metastasis. M0: No distant metastasis.  This staging applies to carcinomas and carcinosarcomas. (AJCC 7th ed.)


Stage III Uterine Corpus Cancer

Stage III includes: III (T3, N0, M0); IIIA (T3a, N0, M0); IIIB (T3b, N0, M0); IIIC (T1-T3, N1/N2, M0); IIIC1 (T1-T3, N1, M0); IIIC2 (T1-T3, N2, M0). T3: Tumor involves serosa and/or adnexa, vagina, or parametrial tissue. T3a: Tumor involves serosa and/or adnexa (direct extension or metastasis). T3b: Tumor involves vagina (direct extension or metastasis) or parametrial tissue. N0: No regional lymph node metastasis. N1: Regional lymph node metastasis to pelvic lymph nodes. N2: Regional lymph node metastasis to para-aortic lymph nodes, with or without positive pelvic lymph nodes.  M0: No distant metastasis. This staging applies to carcinomas and carcinosarcomas. (AJCC 7th ed.)


Stage IV Uterine Corpus Cancer

Stage IV includes: IVA: (T4, Any N, M0); IVB: (Any T, Any N, M1). T4: Tumor invades bladder mucosa and/or bowel mucosa (bullous edema is not sufficient to classify a tumor as T4).  M0: No distant metastasis. M1: Distant metastasis (includes metastasis to inguinal lymph nodes, intraperitoneal disease, or lung, liver, or bone.  It excludes metastasis to para-aortic lymph nodes, vagina, pelvic serosa, or adnexa). This staging applies to carcinomas and carcinosarcomas. (AJCC 7th ed.)


Lymphoma, Mixed-Cell, Follicular

A follicular lymphoma which contains 6-15 centroblasts per 40X high-power microscopic field.


Stage III Fallopian Tube Cancer AJCC v7

Stage III includes: (T3, N0, M0); IIIA (T3a, N0, M0); IIIB (T3b, N0, M0); IIIC (T3c, N0, M0); (Any T, N1, M0).  T3: Tumor involves one or both fallopian tubes, with peritoneal implants outside the pelvis.  T3a: Microscopic peritoneal metastasis outside the pelvis.  T3b: Macroscopic peritoneal metastasis outside the pelvis 2 cm or less in greatest dimension.  T3c: Peritoneal metastasis outside the pelvis and more than 2 cm in diameter.  N0: No regional lymph node metastasis.  N1: Regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 7th ed.)


Stage II Esophageal Cancer AJCC v7

Stage II includes: For squamous cell carcinoma: IIA (T2-3, N0, M0, G1, GX, Tumor location: Upper, middle); (T2-3, N0, M0, G2-3, Tumor location: Lower, X); IIB (T2-3, N0, M0, G2-3, Tumor location: Upper, middle); (T1-2, N1, M0, Any G, Tumor location: Any).  For adenocarcinoma: IIA (T2, N0, M0, G3); IIB (T3, N0, M0, Any G); (T1-2, N1, M0, Any G).  T2: Tumor invades muscularis propria. T3: Tumor invades adventitia. T1: Tumor invades lamina propria, muscularis mucosae, or submucosa.  N0: No regional lymph node metastasis.  N1: Metastasis in 1-2 regional lymph nodes.  M0: No distant metastasis.  G1: Well differentiated.  GX: Grade cannot be assessed-stage grouping as G1.  G2: Moderately differentiated.  G3: Poorly differentiated.  Tumor location: Location of the primary cancer site is defined by the position of the upper (proximal) edge of the tumor in the esophagus.  (AJCC 7th ed.)


Stage III Esophageal Cancer AJCC v7

Stage III includes: For squamous cell carcinoma: IIIA (T1-2, N2, M0, Any G, Tumor location: Any); (T3, N1, M0, Any G, Tumor location: Any); (T4a, N0, M0, Any G, Tumor location: Any); IIIB (T3, N2, M0, Any G, Tumor location: Any); IIIC (T4a, N1-2, M0, Any G, Tumor location: Any); (T4b, Any N, M0, Any G, Tumor location: Any); (Any T, N3, M0, Any G, Tumor location: Any).  For adenocarcinoma: IIIA (T1-2, N2, M0, Any G); (T3, N1, M0, Any G); (T4a, N0, M0, Any G); IIIB (T3, N2, M0, Any G); IIIC (T4a, N1-2, M0, Any G); (T4b, Any N, M0, Any G); (Any T, N3, M0, Any G).  T1: Tumor invades lamina propria, muscularis mucosae, or submucosa.  T2: Tumor invades muscularis propria. T3: Tumor invades adventitia. T4a: Resectable tumor invading pleura, pericardium, or diaphragm. T4b: Unresectable tumor invading other adjacent structures, such as aorta, vertebral body, trachea, etc. N0: No regional lymph node metastasis.  N1: Metastasis in 1-2 regional lymph nodes.  N2: Metastasis in 3-6 regional lymph nodes.  N3: Metastasis in seven or more regional lymph nodes.  M0: No distant metastasis.  Tumor location: Location of the primary cancer site is defined by the position of the upper (proximal) edge of the tumor in the esophagus.  (AJCC 7th ed.)


Stage IV Esophageal Cancer AJCC v7

Stage IV includes: For squamous cell carcinoma: Any T, Any N, M1, Any G, Tumor location: Any.  For adenocarcinoma: Any T, Any N, M1, Any G. M1: Distant metastasis.  Tumor location: Location of the primary cancer site is defined by the position of the upper (proximal) edge of the tumor in the esophagus.  (AJCC 7th ed.)


Malignant neoplasm of stomach stage I

Stage I includes: IA (T1, N0, M0); IB (T2, N0, M0); (T1, N1, M0).  T1: Tumor invades lamina propria, muscularis mucosae, or submucosa.  T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis.  N1: Metastasis in 1-2 regional lymph nodes. M0: No distant metastasis. (AJCC 7th ed.)


Malignant neoplasm of stomach stage II

Stage II includes: IIA (T3, N0, M0); (T2, N1, M0); (T1, N2, M0); IIB (T4a, N0, M0); (T3, N1, M0); (T2, N2, M0); (T1, N3, M0).  T1: Tumor invades lamina propria, muscularis mucosae, or submucosa.  T2: Tumor invades the muscularis propria. T3: Tumor penetrates subserosal connective tissue without invasion of visceral peritoneum or adjacent structures.  T4a: Tumor invades serosa (visceral peritoneum).  N0: No regional lymph node metastasis.  N1: Metastasis in 1-2 regional lymph nodes.  N2: Metastasis in 3-6 regional lymph nodes.  N3: Metastasis in seven or more regional lymph nodes.  M0: No distant metastasis. (AJCC 7th ed.)


Malignant neoplasm of stomach stage III

Stage III includes: IIIA (T4a, N1, M0); (T3, N2, M0); (T2, N3, M0); IIIB (T4b, N0, M0); (T4b, N1, M0); (T4a, N2, M0); (T3, N3, M0); IIIC (T4b, N2, M0); (T4b, N3, M0); (T4a, N3, M0).  T2: Tumor invades the muscularis propria. T3: Tumor penetrates subserosal connective tissue without invasion of visceral peritoneum or adjacent structures.  T4a: Tumor invades serosa (visceral peritoneum).  T4b: Tumor invades adjacent structures. N0: No regional lymph node metastasis.  N1: Metastasis in 1-2 regional lymph nodes.  N2: Metastasis in 3-6 regional lymph nodes.  N3: Metastasis in seven or more regional lymph nodes. M0: No distant metastasis.  (AJCC 7th ed.)


Malignant neoplasm of stomach stage IV

Stage IV includes: (Any T, Any N, M1).  M1: Distant metastasis. (AJCC 7th ed.)


Stage II Rectal Cancer AJCC v7

Stage II includes: IIA (T3, N0, M0); IIB (T4a, N0, M0); IIC (T4b, N0, M0). T3: Tumor invades through the muscularis propria into pericolorectal tissues.  T4a: Tumor penetrates to the surface of the visceral peritoneum.  T4b: Tumor directly invades or is adherent to other organs or structures. N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


Stage III Colorectal Cancer AJCC v7

Stage III includes: IIIA (T1-T2, N1/N1c, M0); (T1, N2a, M0); IIIB (T3-T4a, N1/N1c, M0); (T2-T3, N2a, M0); (T1-T2, N2b, M0); IIIC (T4a, N2a, M0); (T3-T4a, N2b, M0); (T4b, N1-N2, M0).  T1: Tumor invades submucosa.  T2: Tumor invades muscularis propria.  T3: Tumor invades through the muscularis propria into pericolorectal tissues.  T4a: Tumor penetrates to the surface of the visceral peritoneum.  T4b: Tumor directly invades or is adherent to other organs or structures. N0: No regional lymph node metastasis.  N1: Metastasis in 1-3 regional lymph nodes.  N1c: Tumor deposit(s) in the subserosa, mesentery, or nonperitonealized pericolic or perirectal tissues without regional lymph node metastasis. N2: Metastasis in four or more regional lymph nodes.  N2a: Metastasis in 4-6 regional lymph nodes.  N2b: Metastasis in seven or more regional lymph nodes.  M0: No distant metastasis.  (AJCC 7th ed.)


Stage IV Colorectal Cancer AJCC v7

Stage IV includes: IVA: (Any T, Any N, M1a); IVB: (Any T, Any N, M1b).  M1a: Metastasis confined to one organ or site (e.g., liver, lung, ovary, nonregional node).  M1b: Metastases in more than one organ/site or the peritoneum. (AJCC 7th ed.)


Persistent Disease

biolink:PhenotypicFeature biolink:DiseaseOrPhenotypicFeature biolink:BiologicalEntity biolink:ThingWithTaxon biolink:NamedThing

A disease that does not go to remission despite treatment.


AIDS-Related Primary Effusion Lymphoma

Primary effusion lymphoma occurring in HIV-positive patients.


Stage III Hepatocellular Carcinoma AJCC v7

Stage III includes: IIIA: (T3a, N0, M0); IIIB: (T3b, N0, M0); IIIC: (T4, N0, M0). T3a: Multiple tumors more than 5 cm. T3b: Single tumor or multiple tumors of any size involving a major branch of the portal vein or hepatic vein.  T4: Tumors(s) with direct invasion of adjacent organs other than the gallbladder or with perforation of visceral peritoneum. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 7th ed.)


Stage IV Hepatocellular Carcinoma AJCC v7

Stage IV includes: IVA: (Any T, N1, M0); IVB: (Any T, Any N, M1). N1: Regional lymph node metastasis. M0: No distant metastasis.  M1: Distant metastasis. (AJCC 7th ed.)


Stage III Gallbladder Cancer AJCC v7

Stage III includes: IIIA (T3, N0, M0); IIIB (T1-3, N1, M0). T3: Tumor perforates the serosa (visceral peritoneum) and/or directly invades the liver and/or one other adjacent organ or structure, such as the stomach, duodenum, colon, pancreas, omentum, or extrahepatic bile ducts.  T1: Tumor invades lamina propria or muscular layer.  T2: Tumor invades perimuscular connective tissue; no extension beyond serosa or into liver. N0: No regional lymph node metastasis.  N1: Metastases to nodes along the cystic duct, common bile duct, hepatic artery, and/or portal vein.  M0: No distant metastasis. (from AJCC 7th Ed.)


Stage IV Gallbladder Cancer AJCC v7

Stage IV includes: IVA (T4, N0-1, M0); IVB (Any T, N2, M0); (Any T, Any N, M1).  T4: Tumor invades the main portal vein or hepatic artery, or invades two or more extrahepatic organs or structures.  N0: No regional lymph node metastasis.  N1: Metastases to nodes along the cystic duct, common bile duct, hepatic artery, and/or portal vein. N2: Metastases to periaortic, pericaval, superior mesenteric artery, and/or celiac artery lymph nodes.  M0: No distant metastasis.  M1: Distant metastasis. (from AJCC 7th Ed.)


FNCLCC Sarcoma Grade 2

A sarcoma with a total score of 4 or 5 according to the FNCLCC guidelines.


FNCLCC Sarcoma Grade 3

A sarcoma with a total score of 6 or higher according to the FNCLCC guidelines.


Stage I Adult Hodgkin Lymphoma

Ann Arbor Classification: Stage I: Involvement of a single lymph node region (I); or localized involvement of a single extralymphatic organ or site in the absence of any lymph node involvement (IE) (rare in Hodgkin lymphoma).


Stage II Adult Hodgkin Lymphoma

Ann Arbor Classification: Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm (II); or localized involvement of a single extralymphatic organ or site in association with regional lymph node involvement with or without involvement of other lymph node regions on the same side of the diaphragm (IIE).


Stage III Adult Hodgkin Lymphoma

Ann Arbor Classification: Stage III: Involvement of lymph node regions on both sides of the diaphragm (III), which also may be accompanied by extralymphatic extension in association with adjacent lymph node involvement (IIIE) or by involvement of the spleen (IIIS) or both (IIIE,S).


Stage IV Adult Hodgkin Lymphoma

Ann Arbor Classification: Stage IV: Diffuse or disseminated involvement of one or more extralymphatic organs, with or without associated lymph node involvement; or isolated extralymphatic organ involvement in the absence of adjacent regional lymph node involvement, but in conjunction with disease in distant site(s); or any involvement of the liver or bone marrow, lungs (other than by direct extension from another site), or cerebrospinal fluid.


Occult Lung Non-Small Cell Carcinoma

A non-small cell lung carcinoma detectable by sputum cytology only.  The primary tumor is undetectable radiographically or during bronchoscopy; therefore, it can not be assessed.


Adult Angiosarcoma

An angiosarcoma occurring in the adult population.


Metastatic Parathyroid Gland Carcinoma

A parathyroid gland carcinoma that has spread to other anatomic sites.


Recurrent Childhood Central Nervous System Neoplasm

The reemergence of central nervous system neoplasm in childhood after a period of remission.


Small cell lung cancer extensive stage

Small cell lung carcinoma which has spread beyond one hemi-thorax and the regional lymph nodes.


Pregnancy Outcome

Findings observed at the end of a pregnancy.


Small cell lung cancer recurrent

The reemergence of small cell carcinoma of the lung after a period of remission.


Recurrent Vulvar Carcinoma

The reemergence of vulvar carcinoma after a period of remission.


Stage I Childhood Lymphoblastic Lymphoma

Stage I: A single tumor or nodal area is involved, excluding the abdomen and mediastinum (from PDQ).


Stage II Childhood Lymphoblastic Lymphoma

Stage II: Disease extent is limited to a single tumor with regional node involvement, 2 or more tumors or nodal areas involved on one side of the diaphragm, or a primary gastrointestinal tract tumor (completely resected) with or without regional node involvement (from PDQ).


Stage III Childhood Lymphoblastic Lymphoma

Stage III: Tumors or involved lymph node areas occur on both sides of the diaphragm. Stage III also includes any primary intrathoracic (mediastinal, pleural, or thymic) disease, extensive primary intra-abdominal disease, or any paraspinal or epidural tumors (from PDQ).


Stage IV Childhood Lymphoblastic Lymphoma

Stage IV: Tumors involve bone marrow and/or central nervous system (CNS) regardless of other sites of involvement (from PDQ).


Recurrent Childhood Lymphoblastic Lymphoma

The reemergence of lymphoblastic lymphoma in childhood after a period of remission.


Adult Burkitt Lymphoma

A Burkitt lymphoma occurring in adults.


Localized Unresectable Adult Hepatocellular Carcinoma

A localized hepatocellular carcinoma that occurs during adulthood and it is not amenable to surgical resection.


Recurrent Adult Hepatocellular Carcinoma

A hepatocellular carcinoma that occurs during adulthood and has recurred after a period of remission.


recurrent childhood acute myeloid leukemia

The reemergence of acute myeloid leukemia in childhood after a period of remission.


Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive

The reemergence of chronic myeloid leukemia, BCR-ABL1 positive after a period of remission.


Recurrent Uterine Corpus Cancer

The reemergence of uterine corpus cancer after a period of remission.


Childhood Diffuse Large Cell Lymphoma

A diffuse large cell lymphoma occurring in children.


Childhood Immunoblastic Lymphoma

An immunoblastic lymphoma (a variant of diffuse large B-cell lymphoma) occurring in children.


Stage I Thyroid Gland Papillary Carcinoma AJCC v7

Stage I includes: Under 45 years: Any T, Any N, M0.  45 years and older: T1, N0, M0.  T1: Tumor size 2 cm or less in greatest dimension, limited to the thyroid gland.  N0: No regional lymph node metastasis.  M0: No evidence of distant metastasis. (from AJCC 7th Ed.)


Stage II Thyroid Gland Papillary Carcinoma AJCC v7

Stage II includes: Under 45 years: Any T, Any N, M1.  45 years and older: T2, N0, M0.  T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension, limited to the thyroid gland.  N0: No regional lymph node metastasis.  M1: Distant metastasis.  M0: No evidence of distant metastasis.  (from AJCC 7th Ed.)


Stage IV Thyroid Gland Papillary Carcinoma AJCC v7

Stage IV includes: IVA (T4a, N0, M0); (T4a, N1a, M0); (T1, N1b, M0); (T2, N1b, M0); (T3, N1b, M0); (T4a, N1b, M0); IVB (T4b, Any N, M0); IVC (Any T, Any N, M1). T4a: Moderately advanced local disease.  Tumor of any size extending beyond the thyroid gland capsule to invade subcutaneous soft tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve.  T1: Tumor size 2 cm or less in greatest dimension, limited to the thyroid gland.  T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension, limited to the thyroid gland.  T3: Tumor more than 4 cm in greatest dimension and limited to the thyroid gland, or tumor of any size with minimal extrathyroid extension (e.g., extension to sternothyroid muscle or perithyroid soft tissues).  T4b: Very advanced disease.  Tumor invades prevertebral fascia or encases carotid artery or mediastinal vessels.  N0: No regional lymph node metastasis.  N1a: Metastasis to pretracheal, paratracheal or prelaryngeal/Delphian lymph nodes (Level VI lymph nodes).  N1b: Metastasis to unilateral, bilateral or contralateral cervical (Levels I, II, III, IV, or V) or retropharyngeal or superior mediastinal lymph nodes (Level VII).  M0: No distant metastasis.  M1: Distant metastasis. (AJCC 7th ed.)


Stage I Thyroid Gland Follicular Carcinoma AJCC v7


Stage II Thyroid Gland Follicular Carcinoma AJCC v7


Stage IV Thyroid Gland Follicular Carcinoma AJCC v7

Stage IV includes: IVA (T4a, N0, M0); (T4a, N1a, M0); (T1, N1b, M0); (T2, N1b, M0); (T3, N1b, M0); (T4a, N1b, M0); IVB (T4b, Any N, M0); IVC (Any T, Any N, M1). T4a: Moderately advanced local disease.  Tumor of any size extending beyond the thyroid gland capsule to invade subcutaneous soft tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve. T1: Tumor size 2 cm or less in greatest dimension, limited to the thyroid gland.  T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension, limited to the thyroid gland.  T3: Tumor more than 4 cm in greatest dimension and limited to the thyroid gland, or tumor of any size with minimal extrathyroid extension (e.g., extension to sternothyroid muscle or perithyroid soft tissues).  T4b: Very advanced disease.  Tumor invades prevertebral fascia or encases carotid artery or mediastinal vessels.  N0: No regional lymph node metastasis.  N1a: Metastasis to pretracheal, paratracheal or prelaryngeal/Delphian lymph nodes (Level VI lymph nodes).  N1b: Metastasis to unilateral, bilateral or contralateral cervical (Levels I, II, III, IV, or V) or retropharyngeal or superior mediastinal lymph nodes (Level VII).  M0: No distant metastasis.  M1: Distant metastasis. (AJCC 7th ed.)


Adult Ependymoma

An ependymoma occurring in adults.


Adult Meningioma

A meningioma that occurs during adulthood.


Childhood Burkitt Lymphoma

A Burkitt lymphoma occurring in children.


Stage IV Cutaneous Melanoma AJCC v6 and v7

Stage IV includes: (Any T, Any N, M1).  M1: Distant metastasis. (from AJCC 6th and 7th Eds.)


Non-small cell lung cancer stage IIIA

Stage IIIA includes: (T1a, N2, M0); (T1b, N2, M0); (T2a, N2, M0); (T2b, N2, M0); (T3, N1, M0); (T3, N2, M0); (T4, N0, M0); (T4, N1, M0).  T4: Lung cancer with a tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, and separate tumor nodule(s) in a different ipsilateral lobe.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension.  N2: Lung cancer with metastasis to ipsilateral mediastinal and/or subcarinal lymph nodes.  M0: No distant metastasis. (AJCC 7th ed.)


Non-small cell lung cancer stage IIIB

Stage IIIB includes: (T1a, N3, M0); (T1b, N3, M0); (T2a, N3, M0); (T2b, N3, M0); (T3, N3, M0); (T4, N2, M0); (T4, N3, M0).  T4: Lung cancer with a tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, and separate tumor nodule(s) in a different ipsilateral lobe.  N2: Lung cancer with metastasis to ipsilateral mediastinal and/or subcarinal lymph nodes.  N3: Lung cancer with metastasis to contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph nodes.  M0: No distant metastasis. (AJCC 7th ed.)


Stage 0 Non-Small Cell Lung Cancer AJCC v6 and v7

Stage 0 includes: Tis, N0, M0.  Tis: Carcinoma in situ.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


Meningeal Chronic Myeloid Leukemia, BCR-ABL1 Positive

Infiltration of the meninges by chronic myeloid leukemia, BCR-ABL1 positive.


Childhood Acute Myeloid Leukemia in Remission

A finding of acute myeloid leukemia of childhood that is not growing and responds to treatment.


Recurrent Neck Squamous Cell Carcinoma of Unknown Primary

The reemergence of metastatic squamous cell carcinoma of unknown primary in the neck region after a period of remission.


Stage III Thyroid Gland Follicular Carcinoma AJCC v7

Stage III includes: (T3, N0, M0); (T1, N1a, M0); (T2, N1a, M0); (T3, N1a, M0). T3: Tumor greater than 4 cm in greatest dimension and limited to the thyroid gland, or tumor of any size with minimal extrathyroid extension (e.g., extension to sternothyroid muscle or perithyroid soft tissues).  T1: Tumor size 2 cm or less in greatest dimension, limited to the thyroid gland.  T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension, limited to the thyroid gland.  N0: No regional lymph node metastasis.  N1a: Metastasis to pretracheal, paratracheal or prelaryngeal/Delphian lymph nodes (Level VI lymph nodes).  M0: No distant metastasis. (AJCC 7th ed.)


Stage III Thyroid Gland Papillary Carcinoma AJCC v7


Childhood Lymphoblastic Lymphoma

A lymphoblastic lymphoma occurring in children.


Adult Nodular Sclerosis Classical Hodgkin Lymphoma

Nodular sclerosis classic Hodgkin lymphoma occurring in adults.


Adult Mixed Cellularity Classical Hodgkin Lymphoma

Mixed cellularity classic Hodgkin lymphoma occurring in adults.


Adult Rhabdomyosarcoma

An aggressive malignant mesenchymal neoplasm arising from skeletal muscle in adults.


Adult Acute Myeloblastic Leukemia

An acute myeloid leukemia occurring in adults.


Adult Acute Promyelocytic Leukemia with PML-RARA

An acute promyelocytic leukemia with t(15;17)(q24.1;q21.2); PML-RARA occurring in adults.


Adult Acute Monoblastic Leukemia

An acute monoblastic leukemia occurring in adults.


Childhood Acute Myeloid Leukemia without Maturation

An acute myeloid leukemia without maturation occurring in children.


Childhood Acute Monoblastic Leukemia

An acute monoblastic leukemia occurring in children.


Childhood Acute Monocytic Leukemia

An acute monocytic leukemia occurring in children.


Childhood Acute Eosinophilic Leukemia

An acute eosinophilic leukemia occurring in children.


adenocarcinoma of gallbladder with squamous metaplasia

An infiltrating adenocarcinoma of the gallbladder characterized by the presence of metaplastic changes of the malignant glandular cells to squamous cells.


Non-Metastatic Gestational Trophoblastic Tumor

Gestational trophoblastic tumor that is confined to the site in which it initially manifested.


Good Prognosis Metastatic Gestational Trophoblastic Tumor

Metastatic gestational trophoblastic tumor in which risk factors are absent.


Poor Prognosis Metastatic Gestational Trophoblastic Tumor

Metastatic gestational trophoblastic tumor in which risk factors are present.


Stage IV Uterine Sarcoma AJCC v7

Stage IV includes: IVA (T4, Any N, M0); IVB (Any T, Any N, M1).  T4: Tumor involves bladder or rectum.  M0: No distant metastasis.  M1: Distal metastasis (excluding adnexa, pelvic and abdominal tissues).  This staging applies to leiomyosarcoma, endometrial stromal sarcoma, and adenosarcoma. (AJCC 7th ed.)


Recurrent Carcinoma of Unknown Primary

The reemergence of carcinoma from an unknown primary after a period of remission.


Stage I Childhood Burkitt Lymphoma

Ann Arbor Classification: Stage I: Involvement of a single lymph node region (I); or localized involvement of a single extralymphatic organ or site in the absence of any lymph node involvement (IE).


Stage II Childhood Burkitt Lymphoma

Ann Arbor Classification: Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm (II); or localized involvement of a single extralymphatic organ or site in association with regional lymph node involvement with or without involvement of other lymph node regions on the same side of the diaphragm (IIE).


Stage III Childhood Burkitt Lymphoma

Ann Arbor Classification: Stage III: Involvement of lymph node regions on both sides of the diaphragm (III), which also may be accompanied by extralymphatic extension in association with adjacent lymph node involvement (IIIE) or by involvement of the spleen (IIIS) or both (IIIE,S).


Stage IV Childhood Burkitt Lymphoma

Ann Arbor Classification: Stage IV: Diffuse or disseminated involvement of one or more extralymphatic organs, with or without associated lymph node involvement; or isolated extralymphatic organ involvement in the absence of adjacent regional lymph node involvement, but in conjunction with disease in distant site(s); or any involvement of the liver or bone marrow, lungs (other than by direct extension from another site), or cerebrospinal fluid.


Recurrent Childhood Burkitt Lymphoma

The reemergence of Burkitt lymphoma in childhood after a period of remission.


Recurrent Childhood Brain Stem Glioma

The reemergence of brain stem glioma in childhood after a period of remission.


Recurrent Childhood Cerebral Astrocytoma

The reemergence of cerebral astrocytoma in childhood after a period of remission.


Ann Arbor Stage II Contiguous Adult Burkitt Lymphoma

Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm (II) or localized involvement of a single associated extralymphatic organ or site and its regional lymph nodes with or without other lymph node regions on the same side of the diaphragm (IIE). Note: The number of lymph node regions involved may be indicated by a subscript (e.g., II3). (from PDQ)


Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma


Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma


Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma


Stage II Non-Contiguous Adult Diffuse Small Cleaved Cell Lymphoma


Ann Arbor Stage II Non-Contiguous Mantle Cell Lymphoma


Stage II Non-Contiguous Adult Diffuse Mixed Cell Lymphoma


Ann Arbor Stage II Non-Contiguous Adult Burkitt Lymphoma


Stage I Cervical Cancer AJCC v6 and v7

Stage I includes: I (T1, N0, M0); IA (T1a, N0, M0); IA1 (T1a1, N0, M0); IA2 (T1a2, N0, M0); IB (T1b, N0, M0); IB1(T1b1, N0, M0); IB2 (T1b2, N0, M0). T1: Cervical carcinoma confined to uterus (extension to corpus should be disregarded). T1a: Invasive carcinoma diagnosed only by microscopy. Stromal invasion with a maximum depth of 5.0 mm measured from the base of the epithelium and a horizontal spread of 7.0 mm or less. Vascular space involvement, venous or lymphatic, does not affect classification. T1a1: Measured stromal invasion 3.0 mm or less in depth and 7.0 or less horizontal spread.  T1a2: Measured stromal invasion more than 3.0mm and not more than 5.0 mm with a horizontal spread 7.0mm or less. T1b: Clinically visible lesion confined to the cervix or microscopic lesion greater than T1a/IA2. T1b1: Clinically visible lesion 4.0 cm or less in greatest dimension. T1b2: Clinically visible lesion more than 4.0 cm in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)


Stage III Cervical Cancer AJCC v6 and v7

Stage III includes: III (T3, N0, M0); IIIA (T3a, N0, M0); IIIB (T1, N1, M0), (T2, N1, M0), (T3a, N1, M0), (T3b, Any N, M0). T3: Tumor extends to pelvic wall and/or involves lower third of vagina, and/or causes hydronephrosis or non-functioning kidney. T3a: Tumor involves lower third of vagina, no extension to pelvic wall.  T3b: Tumor extends to pelvic wall and/or causes hydronephrosis or non functioning kidney.  N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)


Stage IV Cervical Cancer AJCC v6 and v7

Stage IV includes: IVA: (T4, Any N, M0); IVB (Any T, Any N, MI). T4: Tumor invades mucosa of bladder or rectum, and/or extends beyond true pelvis (bullous edema is not sufficient to classify a tumor as T4). M1: Distant metastasis. (AJCC 6th and 7th eds.)


Stage III Uterine Corpus Cancer AJCC v6

Stage III includes: III (T3, N0, M0); IIIA (T3a, N0, M0); IIIB (T3b, N0, M0); IIIC (T1, N1, M0); (T2, N1, M0); (T3, N1, M0).  T3: Local and/or regional spread as defined below.  T3a: Tumor invades serosa and/or adnexa (direct extension or metastasis) and/or cancer cells in ascites or peritoneal washings.  T3b Vaginal involvement (direct extension or metastasis). N0: No regional lymph node metastasis. N1: Regional lymph node metastasis to pelvic and/or para-aortic nodes.  M0: No distant metastasis. (AJCC 6th ed.)


Stage I Adrenal Cortex Carcinoma AJCC v7

Stage I includes: T1, N0, M0.  T1: Tumor 5 cm or less in greatest dimension, no extra-adrenal invasion. N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 7th ed.)


Stage II Adrenal Cortex Carcinoma AJCC v7

Stage II includes: T2, N0, M0.  T2: Tumor greater than 5 cm, no extra-adrenal invasion.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


Stage III Adrenal Cortex Carcinoma AJCC v7

Stage III includes: (T1, N1, M0); (T2, N1, M0); (T3, N0, M0).  T1: Tumor 5 cm or less in greatest dimension, no extra-adrenal invasion.  T2: Tumor greater than 5 cm, no extra-adrenal invasion.  T3: Tumor of any size with local invasion, but not invading adjacent organs.  N1: Metastasis in regional lymph node(s).  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


Stage IV Adrenal Cortex Carcinoma AJCC v7

Stage IV includes: (T3, N1, M0); (T4, N0, M0); (T4, N1, M0); (Any T, Any N, M1).  T3: Tumor of any size with local invasion, but not invading adjacent organs.  T4: Tumor of any size with invasion of adjacent organs.  N1: Metastasis in regional lymph node(s).  N0: No regional lymph node metastasis.  M0: No distant metastasis. M1: Distant metastasis.  (AJCC 7th ed.)


Mental disorder in childhood

A category of psychiatric disorders which includes disorders most commonly identified in infancy, childhood, or adolescence.


Recurrent Childhood Malignant Germ Cell Tumor

The reemergence of a malignant germ cell tumor in children after a period of remission.


Non-Hematologic Malignancy

A malignant neoplasm that arises from a site other than the bone marrow and lymphoid tissue.


Terminal illness

An illness that has a prognosis of death.


recurrent gastric cancer

The reemergence of gastric carcinoma after a period of remission.


Recurrent Rectal Cancer

The reemergence of rectal carcinoma after a period of remission.


Mesothelioma malignant localised

A malignant mesothelioma with the gross appearance of a circumscribed serosal lesion and the microscopic appearance of diffuse malignant mesothelioma, without evidence of diffuse spread.


Nasopharyngeal cancer recurrent

The reemergence of nasopharyngeal carcinoma after a period of remission.


Relapsed Hypopharynx Carcinoma

The reemergence of hypopharyngeal carcinoma after a period of remission.


Aggressive Non-Hodgkin Lymphoma

A non-Hodgkin lymphoma with an aggressive clinical course.  Representative examples include Burkitt lymphoma, mantle cell lymphoma, and angioimmunoblastic T-cell lymphoma.


BRAF V600K Mutation Present

A molecular finding indicating the presence of a BRAF V600K mutation in a tissue sample.


Recurrent Anaplastic Large Cell Lymphoma

The reemergence of anaplastic large cell lymphoma after a period of remission.


Recurrent Non-Hodgkin Lymphoma

The reemergence of non-Hodgkin lymphoma after a period of remission.


Large cell lung cancer stage III

Stage III includes: IIIA (T1a, N2, M0); (T1b, N2, M0); (T2a, N2, M0); (T2b, N2, M0); (T3, N1, M0); (T3, N2, M0); (T4, N0, M0); (T4, N1, M0) and IIIB (T1a, N3, M0); (T1b, N3, M0); (T2a, N3, M0); (T2b, N3, M0); (T3, N3, M0); (T4, N2, M0); (T4, N3, M0).  T4: Lung cancer with a tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, and separate tumor nodule(s) in a different ipsilateral lobe.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension.  N2: Lung cancer with metastasis to ipsilateral mediastinal and/or subcarinal lymph nodes.  N3: Lung cancer with metastasis to contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph nodes.  M0: No distant metastasis. (AJCC 7th ed.)


Oral neoplasm malignant recurrent

Reemergence of a lip or oral cavity malignant neoplasm after a period of remission.


Recurrent Hepatocellular Carcinoma

The reemergence of hepatocellular carcinoma after a period of remission


Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7

Stage 0a includes: Ta, N0, M0. Ta: Papillary noninvasive carcinoma.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


Advanced cancer

A malignant neoplasm that has spread extensively to other anatomic sites or is no longer responding to treatment.


Birthing Labor

Uterine contractions resulting in cervical change (dilation and/or effacement). (reVITALize)


AIDS-Related Anal Carcinoma

A carcinoma arising from the anus and occurring in HIV-positive patients. Homosexual HIV-positive men have an increased risk of developing anal squamous cell carcinoma in comparison to the general male population. Sexually transmitted human papillomavirus is detected in the majority of the cases.


Fetal bradycardia

A fetal heart rate below 110 bpm that is sustained for longer than 10 minutes.


AIDS-Related Hodgkin Lymphoma

Hodgkin lymphoma secondary to AIDS. An increased incidence of Hodgkin lymphomas has been observed in HIV positive patients. Most cases are morphologically classified as lymphocyte depleted or mixed cellularity Hodgkin lymphomas.


High-Risk Pregnancy

A fetal/maternal condition that is risky and portends complications for the mother and/or fetus, when compared to a normal pregnancy.


Hormone Imbalance

An abnormal finding indicating that the level of a particular hormone is not within the expected normal values.


Maternal Hypotension

A symptomatic decrease in baseline systolic or diastolic blood pressure in a pregnant woman that requires intervention.


Missed Menstrual Period

The absence of a menstrual period based on the expected start date of the menstrual cycle.


systemic mastocytosis with an associated clonal hematologic non-mast cell lineage disease

Systemic mastocytosis with an associated clonal hematological non-mast cell lineage disease is a form of systemic mastocytosis (SM) associated with malignancy (other than mast cell leukemia).


Second Stage of Labor

A stage during labor and childbirth when the cervix is effaced totally and remains dilated until the birth of the baby.


Uterine Contraction

A tightening of the involuntary smooth muscles of the uterus.


Latent Phase of Labor

From the onset of labor to the onset of the active phase. (reVITALize)


Chronic Bacterial Prostatitis

A chronic infection of the prostate gland caused by bacteria.  It is manifested with recurring urinary tract infections.  The culture of the prostatic fluid, semen, or post-massage urine specimen reveals the presence of bacteria.


PSA Failure

An increase in serum prostate-specific antigen (PSA) levels following treatment for prostate cancer.


Peripheral T-cell lymphoma unspecified refractory

Peripheral T-cell lymphoma, not otherwise specified that is resistant to treatment.


Adult Lymphoblastic Lymphoma

A lymphoblastic lymphoma occurring in adults.


Testis cancer recurrent

Malignant testicular germ cell tumor reemerging after a period of remission.


Adult Brain Glioblastoma

A brain glioblastoma that occurs during adulthood.


Adult Acute Myeloid Leukemia without Maturation

An acute myeloid leukemia without maturation occurring in adults.


Childhood Acute Myeloid Leukemia with Maturation

An acute myeloid leukemia with maturation occurring in children.


High Grade Sarcoma

A sarcoma with the morphologic features of a high-grade tumor and lack of cellular differentiation.


Androgen Receptor Positive

An indication that expression of androgen receptor has been detected in a sample.


Pleural Effusion, Malignant

A collection of fluid in the pleural cavity resulting from malignant disease. Malignant pleural effusions often contain free-floating malignant cells.


Female sexual arousal disorder

A disorder characterized by a recurrent or persistent inability to attain or maintain until completion of sexual activity an adequate physical response of sexual excitement, consisting of vasocongestion in the pelvis, vaginal lubrication and expansion, and swelling of the external genitalia.


Undifferentiated schizophrenia

A subtype of schizophrenia in which the individual exhibits the characteristic symptoms of schizophrenia but the overall picture is not one of catatonic type, paranoid type, or disorganized type schizophrenia.


Transient psychotic episodes

Relatively short-lived periods of psychosis are characterized by the sudden onset of severe disturbances in perception, thinking, and behavior. These episodes typically last for a brief duration, generally ranging from a few days to a few weeks, and are often triggered by a significant stressor or traumatic event.


Radiation necrosis

Tissue necrosis due to radiation exposure.


Bisphosphonate-associated osteonecrosis

Necrosis of the mandible or maxilla in patients receiving intravenous or oral bisphosphonate therapy.  It usually manifests with slow healing or failure to heal of a jaw bone following oral surgery.  In a minority of cases, the necrosis appears spontaneously.  Signs and symptoms include pain, swelling and infection of the affected area.


Best Overall Response

The most clinically favorable response recorded from the start of the study treatment until the end of treatment.


Multicentric Breast Carcinoma

A breast carcinoma characterized by the presence of multiple cancerous tumors that originate from different clones and are usually located in different quadrants of the breast.


Lower Urinary Tract Symptoms

Symptoms that result from pathologic processes affecting the urinary bladder and/or urethra. They include urinary frequency and urgency, dysuria, nocturia, incomplete voiding, and poor stream during urination.


Early Stage Breast Carcinoma

Breast carcinoma that has not spread beyond the breast and the axillary lymph nodes.


Stage III Childhood Non-Hodgkin Lymphoma

Ann Arbor Classification: Stage III: Involvement of lymph node regions on both sides of the diaphragm (III), which also may be accompanied by extralymphatic extension in association with adjacent lymph node involvement (IIIE) or by involvement of the spleen (IIIS) or both (IIIE,S).


Stage IV Childhood Non-Hodgkin Lymphoma

Ann Arbor Classification: Stage IV: Diffuse or disseminated involvement of one or more extralymphatic organs, with or without associated lymph node involvement; or isolated extralymphatic organ involvement in the absence of adjacent regional lymph node involvement, but in conjunction with disease in distant site(s); or any involvement of the liver or bone marrow, lungs (other than by direct extension from another site), or cerebrospinal fluid.


Locally Recurrent Malignant Neoplasm

The reemergence of a malignant neoplasm after a period of remission at the site of the original tumor or adjacent to it.


Ann Arbor Stage I AIDS-Related Lymphoma

Ann Arbor Classification: Stage I: Involvement of a single lymph node region (I); or localized involvement of a single extralymphatic organ or site in the absence of any lymph node involvement (IE) (rare in Hodgkin lymphoma).


Ann Arbor Stage II AIDS-Related Lymphoma

Ann Arbor Classification: Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm (II); or localized involvement of a single extralymphatic organ or site in association with regional lymph node involvement with or without involvement of other lymph node regions on the same side of the diaphragm (IIE).


Ann Arbor Stage III AIDS-Related Lymphoma


Ann Arbor Stage IV AIDS-Related Lymphoma


Congenital Bone Marrow Failure Syndromes

A group of inherited genetic hematopoietic stem cell disorders characterized by bone marrow failure that involves one or more cell lines. Representative examples include Fanconi anemia, Diamond-Blackfan anemia, and Shwachman-Diamond syndrome.


Stage III Borderline Ovarian Surface Epithelial-Stromal Tumor

Stage III includes: T3, N0, M0.  T3: Tumor involves one or both ovaries with microscopically confirmed peritoneal metastasis outside pelvis.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


Stage IV Borderline Ovarian Surface Epithelial-Stromal Tumor

Stage IV includes: Any T, Any N, M1.  M1: Distant metastasis (excludes peritoneal metastasis). (AJCC 6th and 7th eds.)


Systemic Inflammatory Response Syndrome

A generalized state of dysregulated inflammation induced by noninfectious processes. It is characterized by two or more of the following signs and symptoms: fever or hypothermia, increased heart rate, increased respiratory rate, and abnormal white blood cell count.


Erythroleukoplakia

Leukoplakia of the oral mucosa that is clinically characterized by the presence of erythematous or red and white patches.


Drug Resistant Epilepsy

Epilepsy that is refractory to treatment.


Magnocellular nevus

A benign neoplastic melanocytic proliferation within or adjacent to the optic disk. It presents as a pigmented, intraocular tumor.


Stage 4S neuroblastoma

Localized primary tumor, as defined for stage 1, 2A, or 2B, with dissemination limited to skin, liver, and/or bone marrow (limited to infants younger than 1 year). Marrow involvement should be minimal (i.e., <10% of total nucleated cells identified as malignant by bone biopsy or by bone marrow aspirate). More extensive bone marrow involvement would be considered stage 4 disease. The results of the MIBG scan, if performed, should be negative for disease in the bone marrow. (cancer.gov)


Substance-Induced Sleep Disorder

A sleep disorder (insomnia, hypersomnia, or parasomnia) for which there is strong evidence that the disorder is etiologically linked to the direct physiological effects of a substance (i.e., a drug of abuse, a medication, or toxin exposure).


Stage IIIC1 Uterine Corpus Cancer AJCC v7

Stage IIIC1 includes: T1-T3, N1, M0.  T1: Tumor confined to corpus uteri.  T2: Tumor invades stromal connective tissue of the cervix but does not extend beyond uterus.  T3: Tumor involves serosa and/or adnexa, vagina, or parametrial tissue. N1: Regional lymph node metastasis to pelvic lymph nodes. M0: No distant metastasis. This staging applies to carcinomas and carcinosarcomas. (AJCC 7th ed.)


Stage IIIC2 Uterine Corpus Cancer AJCC v7

Stage IIIC2 includes: T1-T3, N2, M0. T1: Tumor confined to corpus uteri.  T2: Tumor invades stromal connective tissue of the cervix but does not extend beyond uterus.  T3: Tumor involves serosa and/or adnexa, vagina, or parametrial tissue.  N2: Regional lymph node metastasis to para-aortic lymph nodes, with or without positive pelvic lymph nodes.  M0: No distant metastasis. This staging applies to carcinomas and carcinosarcomas. (AJCC 7th ed.)


A high grade poorly differentiated carcinoma arising from the digestive system.  It is composed of small or large neoplastic cells that express immunohistochemical evidence of neuroendocrine differentiation.  There is marked nuclear atypia, necrosis, and more than 20 mitoses per 10 HPF.


Vaginal Hemorrhage

Bleeding originating from the vagina.


Second Primary Cancers

A primary malignant neoplasm in a patient who has been already diagnosed with a primary malignant neoplasm in another anatomic site.


Esophageal Neuroendocrine Carcinoma

An aggressive, high-grade, and poorly differentiated carcinoma with neuroendocrine differentiation that arises from the esophagus. The mitotic count is more than 20 per 10 HPF. It is classified as either small or large cell neuroendocrine carcinoma based on the size of the malignant cells, the prominence of the nucleoli, and the amount of cytoplasm.


Gastric dysplasia

A intraepithelial neoplasia (dysplasia) that arises in either the native gastric mucosa or in metaplastic gastric epithelium.  It has a flat, polypoid or slightly depressed growth pattern.  It is graded as low grade (mild dysplasia) or high grade (moderate dysplasia and carcinoma in situ).  (WHO, 2000)


Gastric neuroendocrine carcinoma

An aggressive, high-grade, and poorly differentiated carcinoma with neuroendocrine differentiation that arises from the stomach. The mitotic count is more than 20 per 10 HPF. It is classified as either small or large cell neuroendocrine carcinoma based on the size of the malignant cells, the prominence of the nucleoli, and the amount of cytoplasm.


Metastatic malignant neoplasm to stomach

A malignant neoplasm that has spread to the stomach from another organ or system, or from another primary gastric tumor. The primary gastric tumor is not in continuity with the metastatic lesion.  Representative examples of metastatic malignant neoplasms to the stomach include breast, lung, and esophageal metastatic carcinomas and melanomas.


p16-Positive Neoplastic Cells Present

An immunohistochemical test result indicating that there are neoplastic cells stained positive with the p16 INK4a monoclonal antibody.


Monomorphic epitheliotropic intestinal T-cell lymphoma

A mature T-cell and NK-cell non-Hodgkin lymphoma of intraepithelial T-lymphocytes. It usually arises from the small intestine. A minority of cases arise from the large intestine or the stomach. It is characterized by the presence of a monomorphic cellular infiltrate of small to medium-sized T-lymphocytes that are cytotoxic and express CD56. It is not associated with celiac disease.


small intestine neuroendocrine tumor, well differentiated, low or intermediate grade

A well differentiated, low or intermediate grade tumor with neuroendocrine differentiation that arises from the small intestine.


Intestinal Neuroendocrine Carcinoma

An aggressive, high-grade, and poorly differentiated carcinoma with neuroendocrine differentiation that arises from the small or large intestine. The mitotic count is more than 20 per 10 HPF. It is classified as either small or large cell neuroendocrine carcinoma based on the size of the malignant cells, the prominence of the nucleoli, and the amount of cytoplasm.


Digestive System Neuroendocrine Tumor G2

A well differentiated, intermediate grade neoplasm with neuroendocrine differentiation that arises from the digestive system. The mitotic count is 2-20 per 10 HPF and/or the Ki67 index is 3 to 20 percent.


Chronic acalculous cholecystitis

Chronic cholecystitis not associated with the presence of gallstones.


Colorectal Adenomatous Polyp

A polypoid adenoma that arises from and protrudes into the lumen of the colon or rectum.  Epithelial dysplasia is always present.  According to the architectural pattern it is classified as tubular, tubulovillous, or villous.


undifferentiated carcinoma of anal canal

A usually aggressive malignant epithelial neoplasm that arises from the anal canal.  It is composed of malignant cells which do not display evidence of glandular or squamous differentiation.


neuroendocrine carcinoma of anal canal

An aggressive, high-grade, and poorly differentiated carcinoma with neuroendocrine differentiation that arises from the anal canal. The mitotic count is more than 20 per 10 HPF. It is classified as either small or large cell neuroendocrine carcinoma based on the size of the malignant cells, the prominence of the nucleoli, and the amount of cytoplasm.


Inflammatory Hepatocellular Adenoma

A hepatocellular adenoma that occurs more often in women.  It is characterized by increased levels of inflammation-associated proteins.  It is usually associated with steatosis and obesity.


Metastatic carcinoma to liver

A carcinoma that has spread to the liver from another primary anatomic site.  Representative examples include metastatic carcinomas from the colon, breast, and lung.


Gallbladder Adenocarcinoma, Biliary Type

A well or moderately differentiated adenocarcinoma that arises from the gallbladder.  It is the most common type of gallbladder carcinoma and is characterized by the presence of malignant tubular glands.  Intestinal differentiation may be present.


Hematospermia

A finding indicating the presence of blood in the semen.


Extrahepatic Bile Duct Adenocarcinoma, Biliary Type

A well or moderately differentiated adenocarcinoma that arises from the extrahepatic bile ducts.  It is characterized by the presence of malignant tubular glands.


Human Papillomavirus-Related Adenosquamous Carcinoma

An adenosquamous carcinoma associated with the presence of human papillomavirus infection.


Acute Rejection

Rejection of a transplanted organ that usually occurs after the first week of the transplantation.  The risk of acute rejection is highest in the first three months following transplantation.  Morphologically, there is an inflammatory infiltrate composed of lymphocytes and neutrophils and vascular damage in the rejected tissue.


Associated Pulmonary Arterial Hypertension

Pulmonary hypertension that results from another disorder (e.g., connective tissue disorder).


Visual impairment

Visual impairment (or vision impairment) is vision loss (of a person) to such a degree as to qualify as an additional support need through a significant limitation of visual capability resulting from either disease, trauma, or congenital or degenerative conditions that cannot be corrected by conventional means, such as refractive correction, medication, or surgery.


Maternal Obesity

Obesity in a female who has a child.


Acquired methemoglobinemia

Methemoglobinemia that is caused by exposure to certain drugs (xylocaine and benzene) and nitrate-rich foods.


Sickle Beta 0 Thalassemia

A form of sickle cell thalassemia characterized by the absence of hemoglobin A. Patients usually have severe anemia identical to that seen in sickle cell disease.


Sickle Beta Plus Thalassemia

A mild form of sickle cell thalassemia characterized by the presence of hemoglobin S and a small amount of hemoglobin A in the red blood cells. It is characterized by the presence of small red blood cells and mild anemia.


Syndrome of infant of diabetic mother

An infant that was born to a mother who persistently had high glucose blood levels during pregnancy. The infants of diabetic mothers are large for their gestational age and may develop hypoglycemic episodes soon after birth.


Stenosis of intestine

Fibrosis of the wall of a segment of the intestine that leads to intestinal lumen narrowing.


Neonatal disorder

A non-neoplastic or neoplastic disorder which occurs during the neonatal period.


Opiate Withdrawal Syndrome

A syndrome that is defined by signs and symptoms related to abrupt or gradual stoppage of opioids use. They include strong cravings, sweating, nausea, vomiting, irritation, anxiety, muscle pain, dilated pupils and insomnia.


Pneumoperitoneum

Free air within the peritoneal cavity.


Severe Bronchopulmonary Dysplasia

Bronchopulmonary dysplasia that results in severe respiratory complications. The infants with severe symptoms are usually premature, have low birth weight, and the oxygen and ventilation support requirements are increased.


Neuropathic spinal arthropathy

A progressive disorder of vertebral joint degeneration that occurs in the setting of any condition characterized by decreased afferent innervation, involving loss of deep pain and proprioceptive sensation in the vertebral column. Patients most commonly present with symptoms of lower back pain, sitting imbalance, progressive spinal deformity (usually kyphosis), and an audible clicking sound on changing postures.


Neonatal rickets

Rickets that usually affects premature infants. Factors that contribute to the development of neonatal rickets include calcium, phosphorus, or calciferol deficiency. It manifests with spontaneous fractures, respiratory distress, and growth developmental delays.


Adrenoleukodystrophy, Neonatal

A rare metabolic disorder that affects neonates. It is characterized by damage of the white matter in the brain and degeneration of the adrenal glands. It manifests with hyperactivity, paralysis, muscular weakness, crossed eyes, hearing loss, seizures, and coma.


Neonatal Opiate Withdrawal Syndrome

A constellation of neurobehavioral features observed in a neonate following cessation or reduction of postnatal exposure to opioids.


Autoimmune cytopenia

Cytopenia caused by autoantibodies against the red blood cells, neutrophils, and/or platelets.


Left Ventricular Ejection Fraction

The fraction of the left ventricular end diastolic volume ejected with each beat. The left ventricular ejection fraction is equal to the left ventricular stroke volume divided by the left ventricular end diastolic volume.


Fractional Flow Reserve of Vessel

A lesion-specific measure of stenosis severity within a blood vessel.


Hemodynamic instability

A state of hypoperfusion that does not support normal organ perfusion or function. It can include periods of reduced, unstable, or abnormal blood pressure with near syncope, or episodes of syncope.


Chronic Total Occlusion Vessel

A longstanding, complete blockage of a vessel. (ACC)


Birt-Hogg-Dube syndrome 1

Any Birt-Hogg-Dube (BHD) syndrome in which the cause of the disease is a variation in the FLCN gene.


moderately severe hemophilia A

Moderately severe hemophilia A is a form of hemophilia A characterized by factor VIII deficiency leading to abnormal bleeding as a result of minor injuries, or following surgery or tooth extraction.


hypotrichosis simplex

Hypotrichosis simplex (HS) or hereditary hypotrichosis simplex (HHS) is characterized by reduced pilosity over the scalp and body (with sparse, thin, and short hair) in the absence of other anomalies.


sparsentan

A biphenyl that is 1,1'-biphenyl substituted by (4,5-dimethyl-1,2-oxazol-3-yl)aminosulfonyl, ethoxymethyl, and (2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl groups at positions 2, 2' and 4', respectively. It is a dual antagonist of endothelin and angiotensin II receptors approved for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progression.


perfluorohexyloctane

A fluoroalkane that is tetradecane in which all of the hydrogen atoms at positions 1, 2, 3, 4, 5, and 6 have been replaced by fluorine atoms. It is an ophthalmic solution used to treat the signs and symptoms of dry eye disease.


trofinetide

A tripeptide comprising of glycine, 2-methyl-L-proline, and L-glutamic acid joined in sequence by peptide linkages.  It is the first and only treatment approved by the FDA specifically indicated for Rett syndrome in adults and pediatric patients two years of age and older.


dasatinib monohydrate

A hydrate that is the monohydrate of dasatinib. It is used for the treatment of chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia. Note that the name 'dasatinib' is used to refer to the monohydrate (USAN) as well as to anhydrous dasatinib (INN).


talazoparib tosylate

Talazoparib is an orally available small molecule inhibitor of the DNA repair enzyme poly ADP-ribose polymerase (PARP) which is used as an antineoplastic agent in the treatment of selected cases of breast cancer. Talazoparib is associated with a moderate rate of serum aminotransferase elevations during therapy and is suspected to cause rare instances of clinically apparent acute liver injury.


colesevelam

A polyallylamine cross-linked with epichlorohydrin and alkylated with 1-bromodecane and 6-bromohexyltrimethylammonium bromide. It is used as its hydrochloride as an orally administered bile acid sequestrant to reduce the amount of cholesterol and certain fatty substances in the blood.


TENOFOVIR

A hydrate that is the monohydrate form of anhydrous tenovir.


barium sulfate

A metal sulfate with formula BaO4S. Virtually insoluble in water at room temperature, it is mostly used as a component in oil well drilling fluid it occurs naturally as the mineral barite.


gadodiamide

A non-ionic gadolinium chelate having a macrocyclic triamine framework. It is used as a paramagnetic contrast agent in magnetic resonance imaging (MRI).


colestipol

A high molecular weight copolymer of diethylenetriamine and epichlorohydrin (hydrochloride), with approximately 1 out of 5 amine nitrogens protonated. Due to the highly cross-linked and insoluble nature of the material, no structural formula has been assigned and no specific molecular weight information is available. A basic anion exchange resin, it is used as its hydrochloride for binding bile acids in the intestine, inhibiting their reabsorption.


pacritinib

An azamacrocycle with formula C28H32N4O3. It is a Janus kinase inhibitor and its citrate salt is approved for the treatment of intermediate or high risk, primary or secondary myelofibrosis.


TACROLIMUS

A hydrate that is the monohydrate form of tacrolimus.


ROSUVASTATIN CALCIUM

An organic calcium salt that is the hemicalcium salt of rosuvastatin.


zavegepant

A member of the class of ureas that is urea in which both amino groups are replaced by 4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidin-1-yl and {(2R)-3-(7-methyl-1H-indazol-5-yl)-1-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]-1-oxopropan-2-yl}amino groups. It is a calcitonin gene-related peptide receptor antagonist whose hydrochloride salt has been approved by the FDA for the acute treatment of migraine.


spinosad

A two-component mixture comprising spinosyn A and spinosyn D in a ratio of approximately 5:1. Obtained from the fermentation of the naturally occurring soil dwelling bacterium Saccharopolyspora spinosa, it is used for the topical treatment of head lice.


cisplatin

A diamminedichloroplatinum compound in which the two ammine ligands and two chloro ligands are oriented in a cis planar configuration around the central platinum ion. An anticancer drug that interacts with, and forms cross-links between, DNA and proteins, it is used as a neoplasm inhibitor to treat solid tumours, primarily of the testis and ovary. Commonly but incorrectly described as an alkylating agent due to its mechanism of action (but it lacks alkyl groups).


leniolisib

A pyridopyrimidine that is 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine substituted by [(3S)-1-propanoylpyrrolidin-3-yl]amino and 6-methoxy-5-(trifluoromethyl)pyridin-3-yl groups at positions 4 and 6, respectively.


gadoteridol

A non-ionic gadolinium chelate having a macrocyclic tetraamine framework. It is used as a paramagnetic contrast agent in magnetic resonance imaging (MRI).


auranofin

An S-glycosyl compound consisting of 2,3,4,6-tetra-O-acetyl-1-thio-beta-D-glucopyranose with the sufur atom coordinated to (triethylphosphoranylidene)gold. It is administered orally for the treatment of active progressive rheumatoid arthritis.


selinexor

A member of the class of triazoles that is 1H-1,2,4-triazole substituted by (1Z)-3-oxo-3-[2-(pyrazin-2-yl)hydrazinyl]prop-1-en-1-yl and 3,5-bis(trifluoromethyl)phenyl groups at positions 1 and 3, respectively. It is a prescription medicine approved for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.


omaveloxolone

A semi-synthetic triterpenoid drug. It is an Nrf2 activator that is approved for the treatment of Friedreich's ataxia in adults and adolescents aged 16 years and older.


lotilaner

A member of the class of isoxazoles that is 4,5-dihydro-1,2-oxazole substituted by 4-methyl-5-({2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl}carbamoyl)thiophen-2-yl, trifluoromethyl, and 3,4,5-trichlorophenyl groups at positions 3, 5 and 5, respectively (the 5S-stereoisomer). It is a gamma-aminobutyric acid (GABA)-gated chloride channel inhibitor selective for mites, approved for the treatment of Demodex blepharitis.